Tremfya

(Guselkumab)

Tremfya

Drug updated on 11/14/2023

Dosage FormInjection (subcutaneous: 100 mg/mL)
Drug ClassInterleukin-23 blockers
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
  • For the treatment of adult patients of active psoriatic arthritis.

Product Monograph / Prescribing Information

Document TitleYearSource
Tremfya (guselkumab) Prescribing Information.2020Janssen Biotech, Inc., Horsham, PA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Clinical and pharmacoeconomic combined report.2023CADTH
Efficacy and safety of nail psoriasis targeted therapies: a systematic review.2023American Journal of Clinical Dermatology
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs. 2022NICE
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis.2022Cochrane Database of Systematic Reviews
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. 2022The Journal of Dermatological Treatment
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.2022RMD Open
Assessment report: Tremfya.2021EMA
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. 2021Dermatology and Therapy
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.2021Rheumatology
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. 2021Cochrane Database of Systematic Reviews
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. 2021Journal of the American Academy of Dermatology
Racial/ethnic differences in treatment efficacy and safety for moderate‑to‑severe plaque psoriasis: a systematic review.2021Archives of Dermatological Research
Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis.2021Dermatology and Therapy
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis.2021Journal of Dermatological Treatment
Treatment of erythrodermic psoriasis with biologics: a systematic review.2020Journal of the American Academy of Dermatology
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.2020Journal of Dermatological Treatment
Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis.2020Advances in Therapy
Short-term efficacy and safety of il-17, il-12/23, and il-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials.2019Journal of Immunology Research
Treatment of plaque psoriasis with IL-23p19 blockers: a systematic review and meta-analysis.2019International Immunopharmacology
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.2019PLoS One
Guselkumab for treating moderate to severe plaque psoriasis.2018NICE
Clinical review report: guselkumab (Tremfya).2018CADTH
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.2018Journal of Dermatological Treatment
Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. 2018ICER

Clinical Practice Guidelines

Document TitleYearSource
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.2019Journal of the American Academy of Dermatology